Dyne Therapeutics, Inc. 4

Chief Commercial Officer Johanna Friedl‑Naderer executed an automatic sale of 145 shares of Dyne Therapeutics, Inc. common stock at about $18.33 per share to cover taxes after RSU vesting.

On June 16, 2026, Dyne Therapeutics, Inc. Chief Commercial Officer Johanna Friedl‑Naderer automatically sold 145 shares of Dyne common stock at a weighted average price of $18.33 per share, for approximately $2,657 in total proceeds, solely to cover tax withholding obligations arising from the vesting of previously granted restricted stock units under a pre-arranged Rule 10b5‑1 compliant agreement; following this routine tax‑related sale, she directly held 154,208 shares of common stock, including 123,678 unvested RSUs.

Filing Facts

CIK

1818794

Ticker

DYN

Form

4

Source Type

sec

Accession

0001915598-26-000002

Alert Tier

4